ZIVO Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens
JAN 23, 2024
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)-- Zivo Bioscience, Inc. (OTC PINK: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces positive efficacy results following its recent 42-day coccidiosis challenge study further demonstrating the effectiveness of its novel immune-modulating treatment for coccidiosis in broiler chickens. ZIVO’s product candidate for use in poultry feed is designed to boost immune response, allowing birds to effectively combat coccidiosis and reduce the negative effects of the disease without the use of antibiotics. With these and earlier test results, ZIVO will pursue a partnership with a global animal health company for commercializing its coccidiosis product.
The study design was similar to that of a previously successful 28-day challenge study but was extended through 42 days to replicate real-world conditions of the broiler production industry. The results of the study in which the ZIVO treatment groups and a placebo control were blinded to the independent study contractor confirm previously reported positive effects of ZIVO’s non-antibiotic alternative for maintaining broiler health against coccidiosis. Notably, the study also showed that the performance of ZIVO’s product candidate was comparable to that of a market leading anticoccidial product.
“We are delighted to report results that validate our prior 28-day study in broiler chickens, and we are particularly excited to report that our product performance compared favorably to a market leading product containing an antibiotic and an anti-coccidial chemical. The outcomes of our studies demonstrate that our coccidiosis treatment is efficacious in real-world conditions, yet without the undesirable characteristics associated with antibiotics and chemicals,” said John Payne, Chairman and Chief Executive Officer of ZIVO Bioscience.
“Not only do our results show our candidate’s effectiveness in counteracting or eliminating adverse effects of coccidiosis on gastrointestinal health of broiler chickens, we are confident that similar results will be obtained in the commercial broiler production environment at cost parity with conventional antibiotic and antimicrobial interventions. As a result, our product exhibits promising potential to revolutionize poultry health management. Our next step is to use these results to engage a global animal health partner to complete licensing through the USDA and commercialize the product,” Mr. Payne added.
About Coccidiosis
Coccidiosis is a protozoal disease that causes diarrhea, weight loss, decreased performance and increased mortality in poultry. This disease represents a significant economic challenge for the global poultry industry, as indicated by a 2020 study that estimated annual costs ranging from $10 billion to $17 billioni. Products for treating coccidiosis are mostly antibiotic- or ionophore-based, and no significant new commercial technology has been introduced in the past 60 years. The global poultry industry spends more than $1.5 billion annually on coccidiosis control, primarily using decades-old compounds that industry and consumers alike wish to replace due to the risks of developing drug resistance. Coccidiosis is a common disease for chickens, especially among young chicks, and can be fatal or result in compromised digestion.
Bullish
